Results 31 to 40 of about 93,206 (296)

Immunosuppressant adherence after heart transplantation: a review on detection, prevention, and intervention strategies in a multidisciplinary

Frontiers in Cardiovascular Medicine
Heart transplantation is an effective treatment for end-stage heart disease, and postoperative patients' medication adherence is crucial for transplantation outcomes and long-term survival.
Ziying Fan, Yong Han, Guojun Sun, Zuojun Dong   +3 more
doaj   +1 more source

Survivin and Aurora Kinase A control cell fate decisions during mitosis

Molecular Oncology, EarlyView.
Aurora A interacts with survivin during mitosis and regulates its centromeric role. Loss of Aurora A activity mislocalises survivin, the CPC and BubR1, leading to disruption of the spindle checkpoint and triggering premature mitotic exit, which we refer to as ‘mitotic slippage’.
Hana Abdelkabir, Shalitha Wickrama Arachchige, Sally P. Wheatley   +2 more
wiley   +1 more source

Pedalitin could regulate lipid metabolism and attenuate inflammatory factors in a non-alcoholic fatty liver disease cell model

Journal of Holistic Integrative Pharmacy
Nonalcoholic fatty liver disease (NAFLD) is an escalating global health issue, leading to liver fat accumulation, inflammation, fibrosis, and potential liver failure.
Wanying He, Yaying Yu, Hui He, Qian Huang, Zhiting Liu, Fan Yang, Lin Zhou   +6 more
doaj   +1 more source

Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review

Frontiers in Genetics, 2023
Minimal residual disease (MRD) refers to a very small number of residual tumor cells in the body during or after treatment, representing the persistence of the tumor and the possibility of clinical progress.
Lemei Zhu, Lemei Zhu, Lemei Zhu, Ran Xu, Leilei Yang, Wei Shi, Yuan Zhang, Yuan Zhang, Yuan Zhang, Juan Liu, Juan Liu, Juan Liu, Xi Li, Jun Zhou, Jun Zhou, Pingping Bing, Pingping Bing   +16 more
doaj   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

ACT001 improves OVX-induced osteoporosis by suppressing the NF-κB/NLRP3 signaling pathway

Molecular Medicine
Osteoporosis (OP) is a common systemic metabolic bone disease characterized by the decrease in bone mass and hyperactivity of osteoclasts. ACT001 is approved as an orphan drug by FDA and has shown multiple protective effects against tissue injury ...
Yuan Li, Jin-Yu Yang, Ma-Li Lin, Tian-Zhu Liu, Wen-Na Lu, Ying Yang, Zhong-Cheng Liu, Jian-Heng Li, Guo-Qiang Zhang, Jian-Shuang Guo   +9 more
doaj   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

Prediction of Stability in Pharmaceutical Preparations XII

Journal of Pharmaceutical Sciences, 1962
Edward R. Garrett
openaire   +2 more sources

European Code Against Cancer, 5th edition – hormone replacement therapy, other common medical therapies and cancer

Molecular Oncology, EarlyView.
The 5th edition of the European Code Against Cancer (ECAC5) contains 14 recommendations on cancer prevention. Here, we update the cancer prevention recommendations regarding the use of hormone replacement therapy (HRT), which is positioned as recommendation number 13 of the ECAC5.
Mangesh A. Thorat, Marc Arbyn, David Baldwin, Xavier Castells, Solveig Hofvind, Urska Ivanus, Carlo Senore, Esther Toes‐Zoutendijk, Carlijn van der Aalst, Carlos Canelo‐Aybar, Fiorella Karina Fernández‐Sáenz, Ariadna Feliu, Hajo Zeeb, Andre L. Carvalho, Erica D'Souza, David Ritchie, Carolina Espina, Iris Lansdorp‐Vogelaar, Andrea DeCensi   +18 more
wiley   +1 more source

Sulfafurazole dimers potentiate chemo-immunotherapy of low immunogenic breast cancer by preventing the PD-L1 exosomes secretion

Acta Pharmaceutica Sinica B
The αPD-L1 antibody-based immune checkpoint blockade therapy is still limited by the poor clinical response rate as it is mainly utilized to block surface PD-L1 on tumor cells while ignoring abundant PD-L1 exosomes secreted in the environment, causing ...
Zheng Wang, Ronghui Yin, Lin Zhang, Shiyu Li, Zhanwei Zhou, Minjie Sun   +5 more
doaj   +1 more source